

Resource Summary Report

Generated by [RRID](#) on Sep 1, 2026

OV-90

RRID:CVCL_3768

Type: Cell Line

Proper Citation

RRID:CVCL_3768

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_3768

Proper Citation: RRID:CVCL_3768

Description: Cell line OV-90 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Ovarian adenocarcinoma

Defining Citation: [PMID:10949993](#), [PMID:11641787](#), [PMID:20204287](#), [PMID:20215515](#), [PMID:22141344](#), [PMID:22328975](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22710073](#), [PMID:23839242](#), [PMID:24023729](#), [PMID:24675677](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27235858](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OV-90

Synonyms: OV90

Cross References: BTO:BTO_0004852, CLO:CLO_0008276, EFO:EFO_0002311, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-3585, ATCC:CRL-11732,

BioGRID_ORCS_Cell_line:393, BioSample:SAMN03471308, BioSample:SAMN10987765, cancercellines:CVCL_3768, CancerTools:161765, Cell_Model_Passport:SIDM01141, ChEMBL-Cells:ChEMBL4295466, ChEMBL-Targets:ChEMBL4296481, CLS:305849, Cosmic:1102815, Cosmic:1113283, Cosmic:1139219, Cosmic:1305311, Cosmic:1709257, Cosmic:2186586, Cosmic-CLP:1240197, DepMap:ACH-000291, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240197, GEO:GSM274704, GEO:GSM659389, GEO:GSM711702, GEO:GSM784576, GEO:GSM851926, GEO:GSM887483, GEO:GSM888564, GEO:GSM1001427, GEO:GSM1001428, GEO:GSM1001492, GEO:GSM1291148, GEO:GSM1374800, GEO:GSM1670314, GEO:GSM2474988, IARC_TP53:20198, IGRhCellID:OV90, LiGeA:CCLE_009, LINCS_LDP:LCL-1523, PharmacDB:OV90_1210_2019, PRIDE:PXD030304, Progenetix:CVCL_3768, PubChem_Cell_line:CVCL_3768, Wikidata:Q54936833

ID: CVCL_3768

Record Creation Time: 20220427T221402+0000

Record Last Update: 20260829T235522+0000

Ratings and Alerts

No rating or validation information has been found for OV-90.

No alerts have been found for OV-90.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gjerde CH, et al. (2026) A 3D ovarian cancer metastasis model using a decellularised peritoneal matrix to study therapy response. *EBioMedicine*, 124, 106135.

Gendrau-Sanclemente N, et al. (2026) Sphingosine-1-Phosphate Receptor 1 Promotes Ovarian Cancer Tumorsphere Proliferation and Metastasis. *International journal of cancer*, 159(3), 768.

Lujano-Olazaba O, et al. (2026) RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. *Cell reports*, 45(7), 117650.

Uno K, et al. (2026) Mesothelial cells promote peritoneal invasion and metastasis of ascites-derived ovarian cancer cells through spheroid formation. *Science advances*, 12(6), eadu5944.

Guo X, et al. (2026) The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads. *iScience*, 29(7), 116390.

Zhang Z, et al. (2026) A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. *Cell*, 189(10), 2898.

Wang Z, et al. (2026) PTEN loss drives B7H3 upregulation via the mTORC2/FOXO/c-Myc axis to promote tumor immune escape in ovarian cancer. *Cell reports*, 45(4), 117198.

Kimura N, et al. (2026) CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. *Cancer research communications*, 6(2), 383.

Elhaw AT, et al. (2026) RHOV Is a Detachment-Responsive Rho GTPase Necessary for Ovarian Cancer Peritoneal Metastasis. *Cancer research*, 86(11), 2623.

Criscuolo D, et al. (2026) CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOV. *Cancer research communications*, 6(1), 201.

Zoeller JJ, et al. (2025) Derivation of AZD5335, a Novel FR??-Targeted TOP1i-Loaded ADC, for the Treatment of FR??-Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5261.

Hu Y, et al. (2025) Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. *Molecular cell*, 85(24), 4602.

Foote JB, et al. (2025) A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer. *Cancer research*, 85(5), 956.

Davies LT, et al. (2025) Plasma-activated media selectively induces apoptotic death via an orchestrated oxidative stress pathway in high-grade serous ovarian cancer cells. *Molecular oncology*, 19(4), 1170.

Kavaklioglu G, et al. (2025) The domesticated transposon protein L1TD1 associates with its ancestor L1 ORF1p to promote LINE-1 retrotransposition. *eLife*, 13.

Cheng YY, et al. (2025) Loss of Predicted Cell Adhesion Molecule MPZL3 Promotes EMT in Ovarian Cancer. *Cancer research communications*, 5(7), 1180.

Abrantes R, et al. (2025) Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. *Cell reports. Medicine*, 6(9), 102350.

Kim D, et al. (2025) Cyclin E1/CDK2 activation defines a key vulnerability to WEE1 kinase inhibition in gynecological cancers. *NPJ precision oncology*, 9(1), 3.

Jones T, et al. (2025) TFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network. *Science advances*, 11(9), eadr9660.

Chandra V, et al. (2025) Mortalin and PINK1/Parkin-Mediated Mitophagy Represent Ovarian Cancer-Selective Targets for Drug Development. *Advanced science (Weinheim,*

Baden-Wurttemberg, Germany), e05592.